294 related articles for article (PubMed ID: 38785992)
21. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J
Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751
[TBL] [Abstract][Full Text] [Related]
22. Long non-coding RNA GAS5 inhibits DDP-resistance and tumor progression of epithelial ovarian cancer via GAS5-E2F4-PARP1-MAPK axis.
Long X; Song K; Hu H; Tian Q; Wang W; Dong Q; Yin X; Di W
J Exp Clin Cancer Res; 2019 Aug; 38(1):345. PubMed ID: 31391118
[TBL] [Abstract][Full Text] [Related]
23. Deep Learning Can Predict Bevacizumab Therapeutic Effect and Microsatellite Instability Directly from Histology in Epithelial Ovarian Cancer.
Wang CW; Lee YC; Lin YJ; Firdi NP; Muzakky H; Liu TC; Lai PJ; Wang CH; Wang YC; Yu MH; Wu CH; Chao TK
Lab Invest; 2023 Nov; 103(11):100247. PubMed ID: 37741509
[TBL] [Abstract][Full Text] [Related]
24. Maintenance therapy for newly diagnosed epithelial ovarian cancer- a review.
Nag S; Aggarwal S; Rauthan A; Warrier N
J Ovarian Res; 2022 Jul; 15(1):88. PubMed ID: 35902911
[TBL] [Abstract][Full Text] [Related]
25. Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?
Klotz DM; Wimberger P
Arch Gynecol Obstet; 2020 Nov; 302(5):1087-1102. PubMed ID: 32833070
[TBL] [Abstract][Full Text] [Related]
26. Protein tyrosine phosphatase receptor type Z1 inhibits the cisplatin resistance of ovarian cancer by regulating PI3K/AKT/mTOR signal pathway.
Wang P; Hu Y; Qu P; Zhao Y; Liu J; Zhao J; Kong B
Bioengineered; 2022 Jan; 13(1):1931-1941. PubMed ID: 35001804
[TBL] [Abstract][Full Text] [Related]
27. Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints.
Ivy SP; Kunos CA; Arnaldez FI; Kohn EC
Expert Opin Investig Drugs; 2019 Sep; 28(9):771-785. PubMed ID: 31449760
[No Abstract] [Full Text] [Related]
28. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive methylome analysis of ovarian tumors reveals hedgehog signaling pathway regulators as prognostic DNA methylation biomarkers.
Huang RL; Gu F; Kirma NB; Ruan J; Chen CL; Wang HC; Liao YP; Chang CC; Yu MH; Pilrose JM; Thompson IM; Huang HC; Huang TH; Lai HC; Nephew KP
Epigenetics; 2013 Jun; 8(6):624-34. PubMed ID: 23774800
[TBL] [Abstract][Full Text] [Related]
30. High Expression of RING Finger Protein 126 Predicts Unfavorable Prognosis of Epithelial Ovarian Cancer.
Wang C; Wen A; Qiao J; Liu Y; Guo Y; Wang W
Med Sci Monit; 2020 Apr; 26():e921370. PubMed ID: 32254065
[TBL] [Abstract][Full Text] [Related]
31. Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer.
Tian H; Yan L; Xiao-Fei L; Hai-Yan S; Juan C; Shan K
Clin Epigenetics; 2019 Oct; 11(1):153. PubMed ID: 31666131
[TBL] [Abstract][Full Text] [Related]
32. Overcoming resistance to PARP inhibitor in epithelial ovarian cancer, are we ready?
Ray-Coquard I; Vanacker H; Le Saux O; Tredan O
EBioMedicine; 2020 Nov; 61():103046. PubMed ID: 33038760
[No Abstract] [Full Text] [Related]
33. Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer.
Wuntakal R; Seshadri S; Montes A; Lane G
Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD011322. PubMed ID: 27356090
[TBL] [Abstract][Full Text] [Related]
34. Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer.
Gralewska P; Gajek A; Marczak A; Rogalska A
J Hematol Oncol; 2020 Apr; 13(1):39. PubMed ID: 32316968
[TBL] [Abstract][Full Text] [Related]
35. Next-generation sequencing-based genomic profiling analysis reveals novel mutations for clinical diagnosis in Chinese primary epithelial ovarian cancer patients.
Zhang L; Luo M; Yang H; Zhu S; Cheng X; Qing C
J Ovarian Res; 2019 Feb; 12(1):19. PubMed ID: 30786925
[TBL] [Abstract][Full Text] [Related]
36. An overview of early investigational therapies for chemoresistant ovarian cancer.
Marchetti C; Ledermann JA; Benedetti Panici P
Expert Opin Investig Drugs; 2015; 24(9):1163-83. PubMed ID: 26206420
[TBL] [Abstract][Full Text] [Related]
37. [The molecular biology of epithelial ovarian cancer].
Leary A; Pautier P; Tazi Y; Morice P; Duvillard P; Gouy S; Uzan C; Gauthier H; Balleyguier C; Lhommé C
Bull Cancer; 2012 Dec; 99(12):1161-73. PubMed ID: 23238064
[TBL] [Abstract][Full Text] [Related]
38. High expression of CETN2 is associated with platinum resistance and poor prognosis in epithelial ovarian cancer.
Qiu PY; Deng XH; Li L
Clin Transl Oncol; 2023 May; 25(5):1340-1352. PubMed ID: 36527574
[TBL] [Abstract][Full Text] [Related]
39. Current and Futuristic Roadmap of Ovarian Cancer Management: An Overview.
Miree O; Srivastava SK; Dasgupta S; Singh S; Rocconi R; Singh AP
Adv Exp Med Biol; 2021; 1330():1-19. PubMed ID: 34339027
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic Pathways Offer Targets for Ovarian Cancer Treatment.
Gyparaki MT; Papavassiliou AG
Clin Breast Cancer; 2018 Jun; 18(3):189-191. PubMed ID: 29042129
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]